رادار التجارب AI | ||
|---|---|---|
حالة التجربة السريرية NCT06404086 لـ كوفيد طويل الأمد، كوفيد-19 طويل الأمد، فرط النوم، اضطراب النوم هي قيد التجنيد. اطلعوا على جميع التفاصيل في عرض البطاقة الخاص برادار التجارب السريرية وأدوات اكتشاف الذكاء الاصطناعي. أو يمكنكم طرح أي سؤال هنا. | ||
تجربة واحدة تطابق معايير الفلتر
عرض البطاقة
العودة إلى البحث
جامعة ديوكRECOVER-SLEEP: Platform Protocol
تفاصيل التجربة السريرية متاحة بشكل أساسي باللغة الإنجليزية. ومع ذلك، يمكن لـ 'رادار التجارب AI' أن يساعدك؛ ما عليك سوى النقر على 'وصف الدراسة' لعرض ومناقشة معلومات التجربة باللغة التي اخترتها.
التجربة السريرية NCT06404086 مصممة لدراسة علاج لـكوفيد طويل الأمد، كوفيد-19 طويل الأمد، فرط النوم، اضطراب النوم. إنها تجربة تدخُّلية من المرحلة الثانية وهي قيد التجنيد. بدأت في ٢٥ محرم ١٤٤٦ هـ مع خطة لتجنيد ١٬٠٧٤ مشاركًا. تقودها جامعة ديوك، ومن المتوقع اكتمالها بحلول ١١ رجب ١٤٤٧ هـ. تم تحديث البيانات الأخيرة من ClinicalTrials.gov في ٢٥ صفر ١٤٤٧ هـ.
الملخص
The platform protocol is designed to be flexible so that it is suitable for a range of study settings and intervention types. Therefore, the platform protocol provides a general protocol structure that can be shared by multiple interventions and allows comparative analysis across the interventions. For example, objectives, measures, and endpoints are generalized in the platform protocol, but intervention-specific features are detailed in separate appendices.
This platform protocol is a prospective, multi-center, multi-arm, randomized controlled platform trial evaluating potential interventions for PASC-mediated sleep disturbances. The hypothesis is that symptoms of sleep and circadian disorders that emerge in patients with PASC can be improved by phenotype-targeted interventions. Specific sleep and circadian disorders addressed in this protocol include sleep-related daytime impairment (referred to as hypersomnia) and complex PASC-related sleep disturbance (reflecting symptoms of insomnia and sleep-wake rhythm disturbance).
وصف مفصل
Interventions will be added to the platform protocol as appendices. Each appendix will leverage all elements of the platform protocol, with additional elements described in the individual appendix.
After completing Baseline assessments, participants will be randomized to an intervention group, which is based on their sleep phenotype, or into a placebo/control group.
العنوان الرسمي
RECOVER-SLEEP: A Platform Protocol for Evaluation of Interventions for Sleep Disturbances in Post-Acute Sequelae of SARS-CoV-2 Infection (PASC)
الحالات الطبية
كوفيد طويل الأمدكوفيد-19 طويل الأمدفرط النوماضطراب النوممعرّفات دراسة أخرى
- Pro00112484
- OTA-21-015G (رقم منحة/تمويل آخر) (NIH Grant to RTI; RTI subcontracting with DCRI)
NCT معرّف
تاريخ البدء (فعلي)
2024-07-31
آخر تحديث مُنشور
2025-08-19
تاريخ الاكتمال (المقدر)
2025-12-31
عدد المشاركين المخطط لهم
١٬٠٧٤
نوع الدراسة
تدخُّلية
المرحلة
المرحلة الثانية
الحالة
قيد التجنيد
الكلمات الرئيسية
PASC
الغرض الأساسي
العلاج
طريقة توزيع المشاركين
عشوائي
نموذج التدخل
التصميم المتوازي
التعمية
ثلاثي
مجموعات/التدخلات
| مجموعة المشاركين/مجموعة | تَدَخُّل/علاج |
|---|---|
أخرىHypersomnia Arm (Appendix A) This is a double-blind, phase 2, randomized, placebo-controlled interventional trial of a wake-promoting drug (modafinil or solriamfetol) to treat hypersomnia, defined by elevated scores (\> 55) on the PROMIS 8a SRI scale, in participants with PASC. Participants will be randomized to study drug or control. Participants who meet the eligibility criteria for modafinil will receive either active modafinil or modafinil-matched control. If modafinil is contraindicated, participants will be assessed for solriamfetol. If participants are eligible for solriamfetol, they will receive either active solriamfetol or solriamfetol-matched control. If solriamfetol is contraindicated, participants will be excluded from Appendix A. Modafinil and solriamfetol will be analyzed as a single wake-promoting drug condition versus control. The intervention duration will be 10 weeks.
Anticipated enrollment is 474 participants. Details about the Hypersomnia Appendix are available under NCT06404099. | Modafinil Modafinil is used off-label based on supporting published evidence in major depressive disorder (antidepressant augmentation), multiple sclerosis-related fatigue, Parkinson disease-related excessive daytime sleepiness, and severe cancer-related fatigue (in patients receiving active treatment). Doses up to 400 mg/day, given as a singleMode dose, have been well tolerated, but there is no consistent evidence that this dose confers additional benefit beyond that of the 200 mg dose.
Study drug administration will total 10 weeks. Modafinil Placebo The placebo will be tooled to look similar to the modafinil tablet, but it will not contain the active ingredient. Modafinil placebo dosing will follow the same titration scheme as modafinil treatment.
Unblinded study personnel will manage modafinil and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators. Solriamfetol The proposed doses and the schedule of dose escalation are consistent with currently approved FDA labeling for solriamfetol for other disorders of excessive daytime sleepiness.
Solriamfetol dosing will total 10 weeks, including 3 weeks for titration and 7 weeks of maintenance. Solriamfetol will be given as a 75 mg tablet (1 or 2 per day) in the morning. The 3-week titration will be facilitated by phone calls between the study team and participants. Titrations in dose will be dependent upon participants' symptoms and tolerance to solriamfetol, with a goal of participants taking the highest dose permitted by symptoms. This dose will be used for the maintenance phase. Solriamfetol Placebo The placebo tablet will be tooled to look similar to the solriamfetol tablet, but it will not contain the active ingredient. Solriamfetol placebo dosing will follow the solriamfetol dosing scheme and goal.
Unblinded study personnel will manage solriamfetol and placebo disbursement to maintain blinding among participants and blinded study personnel, including site investigators. |
أخرىComplex PASC related Sleep Disturbances (CPSD) Arm (Appendix B ) This is a double-blind, phase 2, randomized, placebo-controlled, interventional trial that combines brief education and a tailored sleep timing prescription for CPSD with therapies that modify circadian timing for participants who report poor sleep quality or daytime sleep-related impairment, defined by elevated scores (≥55) on the PROMIS 8b SD scale, in participants with symptoms that occurred or worsened after COVID-19 infection. Interventions involve tailored lighting (TL) and melatonin. Participants will be randomly assigned to 1 of 4 groups: (a) active TL + oral melatonin, (b) active TL + placebo melatonin, (c) placebo TL + oral melatonin, and (d) placebo TL + placebo melatonin. All groups will receive BBT-CPSD. It is a 2x2 factorial design schema. The intervention duration will be 8 weeks.
Anticipated enrollment for this appendix is 600 participants. Additional details about the CPSD Appendix are available under NCT06404112. | ميلاتونين Melatonin dosing will be one tablet of 3 mg immediate release daily consumed 2 hours before the participant's desired bedtime, which is defined as the time at which the participant tries to fall asleep. Melantonin Placebo Melatonin placebo dosing will be one placebo tablet once daily consumed 2 hours before the participant's desired bedtime. Tailored Lighting (TL) Active TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants. Tailored Lighting (TL) Placebo TL will be delivered similarly to both active and placebo groups, but the circadian stimulus (the amount of light) will be different, albeit practically unidentifiable to participants. |
النتيجة الرئيسية
| مقياس النتيجة | وصف القياس | الإطار الزمني |
|---|---|---|
Total number of participants enrolled in each Appendix | Total number of participants enrolled in each Appendix will be reported. Appendix-specific outcome measure data will be reported under the associated NCT#. | 12 months |
معايير الأهلية
الأعمار المؤهلة للدراسة
بالغ, كبار السن
العمر الأدنى للدراسة
18 Years
الجنس المؤهل
الكل
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
≥ 18 years of age at the time of enrollment
Previous suspected, probable, or confirmed SARS-CoV-2 infection, as defined by the Pan American Health Organization:
Suspected* case of SARS-CoV-2 infection - Three options, A through C:
A. Met the clinical OR epidemiological criteria:
- Clinical criteria: Acute onset of fever AND cough (influenza-like illness) OR Acute onset of ANY THREE OR MORE of the following signs or symptoms: fever, cough, general, weakness/fatigue, headache, myalgia, sore throat, coryza, dyspnea, nausea, diarrhea, anorexia;
- Epidemiological criteria: Contact of a probable or confirmed case or linked to a COVID-19 cluster; or B. Presented with acute respiratory infection with a history of fever or measured fever of ≥ 38°C and cough, with onset within the last 10 days, and required hospitalization; or C. Presented with no clinical signs or symptoms, NOR meeting epidemiologic criteria with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.
Probable* case of SARS-CoV-2 infection, defined as having met the clinical criteria above AND was a contact of a probable or confirmed case or is linked to a COVID-19 cluster; or
Confirmed case of SARS-CoV-2 infection - Two options, A through B:
A. Presented with a positive nucleic acid amplification test, regardless of clinical criteria OR epidemiological criteria; or B. Met clinical criteria AND/OR epidemiological criteria (See suspected case A), with a positive professional use or self-test SARS-CoV-2 Antigen-Rapid Diagnostic Test.
* Suspected and probable cases will only be allowed if they occurred before May 1, 2021, and will be limited to 10% of the study population. Otherwise, confirmed cases are required.
New/worse sleep problems following a SARS-CoV-2 infection that have persisted for at least 12 weeks and are still present at the time of consent
PROMIS 8a SRI or 8b SD T Score ≥ 55**
** Screening with both the PROMIS 8a SRI and 8b SD will occur for the phenotype assessment portion of the protocol.
Willing and able to provide informed consent, complete the surveys and clinical assessments, and return for all of the necessary follow-up visits
Adequate method of birth control for participants of child-bearing potential
An individual who meets any of the following criteria will be excluded from participation in this study:
- Known active acute SARS-CoV-2 infection ≤ 4 weeks from consent
- Known pregnancy, breastfeeding, or contemplating pregnancy during the study period
- Untreated sleep apnea (AHI ≥ 15 or severe sleep-related hypoxemia)
- Current night or rotating shift work
- Known history of narcolepsy prior to SARS-CoV-2 infection
- Any non-marijuana illicit drug use within 30 days of informed consent
- Known history of severe mental disorder, such as psychotic disorders and bipolar disorder
- Current or recent use (within the last 14 days) of study intervention or similar intervention to treat the underlying condition, unless a washout period is permitted per appendix*
- Known allergy/sensitivity or any hypersensitivity to components of the study intervention or control*
- Known contraindication(s) to study intervention including prohibited concomitant medications and without the ability to safely hold prohibited concomitant medications (see appendices)*
- Currently receiving/using intervention from another clinical trial that could impact or mask treatment effect; refer to MOP for details
- Any condition that would make the participant, in the opinion of the investigator, unsuitable for the study
(*)If only one study intervention appendix is open at the time of enrollment. If multiple study intervention appendices are open, a participant may be excluded from any study intervention appendix based on contraindications listed in the study intervention appendix, current use of study intervention, or known allergy/sensitivity/hypersensitivity yet remain eligible for the remaining study intervention appendices.
جامعة ديوك544 تجارب سريرية نشطة للاستكشافجهة اتصال مركزية للدراسة
جهة اتصال: Jaelyn R Linski, BA, CCRC, 919-668-8060, [email protected]
جهة اتصال: Barrie L Harper, BSMT (ASCP) PMP, [email protected]
47 مواقع الدراسة في 1 بلدان
Arizona
Banner University Medical Center Phoenix, Phoenix, Arizona, 85006, United States
نشط (التجنيد مغلق)
University of Arizona Banner Medical Center, Tucson, Arizona, 85719, United States
Heidi Erickson, جهة اتصال, 520-626-5287, [email protected]
Parthasarathy Sairam, MD, المحقق الرئيسي
قيد التجنيد
The Southern Arizona VA Health Care System, Tucson, Arizona, 85723, United States
Adnan Abbasi, MD, جهة اتصال
Adnan Abbasi, المحقق الرئيسي
قيد التجنيد
California
Stanford University, Palo Alto, California, 94304, United States
Clete Kushida, MD, جهة اتصال, 650-723-6601, [email protected]
Clete Kushida, MD, المحقق الرئيسي
قيد التجنيد
University of California San Francisco General Hospital, San Francisco, California, 94143, United States
Aric Prather, MD, جهة اتصال
Aric Prather, المحقق الرئيسي
Andrew Krystal, محقق فرعي
قيد التجنيد
Colorado
University of Colorado Anschutz Medical Campus, Aurora, Colorado, 80045, United States
Sarah Jolley, MD, جهة اتصال
Sarah Jolley, MD, المحقق الرئيسي
Kristine Erlandson, محقق فرعي
Neale Lange, محقق فرعي
قيد التجنيد
Denver Health and Hospital Authority, Denver, Colorado, 80204, United States
Edward Gardner, MD, جهة اتصال
Edward Gardner, المحقق الرئيسي
قيد التجنيد
District of Columbia
Howard University Hospital, Washington D.C., District of Columbia, 20060, United States
Peter Whitesell, جهة اتصال
Peter Whitesell, MD, المحقق الرئيسي
Zara Martirosyan, محقق فرعي
Alem Mehari, محقق فرعي
قيد التجنيد
Florida
University of Florida College of Medicine Jacksonville, Jacksonville, Florida, 32209, United States
Carmen Isache, MD, جهة اتصال
Carmen Isache, MD, المحقق الرئيسي
Jorge Verdecia, MD, محقق فرعي
قيد التجنيد
Lakeland Regional Medical Center, Lakeland, Florida, 33805, United States
Debra Seoane, MD, جهة اتصال
Debra Seoane, MD, المحقق الرئيسي
قيد التجنيد
Georgia
Grady Memorial Hospital, Atlanta, Georgia, 30303, United States
Jenny Han, MD, جهة اتصال
Jenny Han, المحقق الرئيسي
Tiffany Walker, محقق فرعي
قيد التجنيد
Morehouse School of Medicine, Atlanta, Georgia, 30310, United States
Priscilla Igho-Pemu, جهة اتصال
Priscilla Igho-Pemu, المحقق الرئيسي
قيد التجنيد
Emory University, Atlanta, Georgia, 30322, United States
Dayna Johnson, MD, جهة اتصال, 404-727-8708, [email protected]
Dayna Johnson, MD, المحقق الرئيسي
Nancy Collop, MD, محقق فرعي
Alex Truong, MD, محقق فرعي
قيد التجنيد
Atlanta VA Medical Center, Decatur, Georgia, 30030, United States
Barry Fields, MD, جهة اتصال
Barry Fields, MD, المحقق الرئيسي
قيد التجنيد
Emory Hope Clinic, Decatur, Georgia, 30030, United States
Wiley Zanthia, MD, جهة اتصال
Wiley Zanthia, المحقق الرئيسي
Nadine Rouphael, محقق فرعي
Cassie Grimsley-Ackerley, محقق فرعي
Kristen Unterberger, محقق فرعي
Veronica Smith, محقق فرعي
Mary Atha, محقق فرعي
Paulina Rebolledo Esteinou, محقق فرعي
Kelley Colleen, محقق فرعي
Srilatha Edupuganti, محقق فرعي
Matthew Collins, محقق فرعي
Zanthia Wiley, محقق فرعي
Daniel Graciaa, محقق فرعي
Jessica Traenkner, محقق فرعي
قيد التجنيد
Illinois
Northwestern Memorial Hospital, Chicago, Illinois, 60611, United States
Phyllis Zee, MD, جهة اتصال
Phyllis Zee, المحقق الرئيسي
Kathryn Reid, محقق فرعي
Paul Chung, محقق فرعي
Alexander Choi, محقق فرعي
Lisa Wolfe, محقق فرعي
Sabra Abbott, محقق فرعي
Mathew Mass, محقق فرعي
قيد التجنيد
Cook County Health Specialty Care Center, Chicago, Illinois, 60612, United States
نشط (التجنيد مغلق)
Rush University Medical Center, Chicago, Illinois, 60612, United States
James Moy, MD, جهة اتصال
James Moy, MD, المحقق الرئيسي
Babak Mokhlesi, MD, محقق فرعي
قيد التجنيد
University of Illinois at Chicago, Chicago, Illinois, 60612, United States
Bharati Prasad, MD, جهة اتصال
Bharati Prasad, MD, المحقق الرئيسي
قيد التجنيد
NorthShore Medical Group, Evanston, Illinois, 60201, United States
Mary Ellen Acree, MD, جهة اتصال, [email protected]
Amanda Caplan, MD, جهة اتصال, 1-224-364-2273, [email protected]
Mary Ellen Acree, MD, المحقق الرئيسي
Oluwadamilola Adeyemi, MD, محقق فرعي
Amanda Caplan, MD, محقق فرعي
Michael Glickman, MD, محقق فرعي
Benjamin Margolis, MD, محقق فرعي
Nicholas Mathenia, MD, محقق فرعي
قيد التجنيد
Saint Francis Medical Center, Peoria, Illinois, 61606, United States
Patrick Whitten, MD, جهة اتصال
Patrick Whitten, المحقق الرئيسي
Ossama Ikladios, محقق فرعي
Subramanyam Chittivelu, محقق فرعي
Kaninika Verma, محقق فرعي
قيد التجنيد
Kansas
University of Kansas Medical Center, Kansas City, Kansas, 66160, United States
Damien Stevens, MD, جهة اتصال
Damien Stevens, المحقق الرئيسي
Diego Mazzotti, محقق فرعي
قيد التجنيد
Kentucky
University of Kentucky, Lexington, Kentucky, 40536, United States
Christopher Simmons, MD, جهة اتصال
Christopher Simmons, MD, المحقق الرئيسي
Robert Murray, محقق فرعي
Sara Pasha, محقق فرعي
Sidney Whiteheart, محقق فرعي
قيد التجنيد
Maryland
Johns Hopkins Bayview Medical Center, Baltimore, Maryland, 21224, United States
Jonathan Jun, MD, جهة اتصال, 410-550-0115, [email protected]
Jonathan Jun, MD, المحقق الرئيسي
Daisy Duan, MD, محقق فرعي
Luu Pham, MD, محقق فرعي
قيد التجنيد
Jadestone Clinical Research, LLC, Silver Spring, Maryland, 20904, United States
Jonathan Cohen, MD, جهة اتصال
Jonathan Cohen, المحقق الرئيسي
Homam Ibrahim, محقق فرعي
قيد التجنيد
Massachusetts
Tufts Medical Center, Boston, Massachusetts, 02111, United States
Aarti Grover, MD, جهة اتصال, 617-636-7689, [email protected]
Aarti Grover, MD, المحقق الرئيسي
قيد التجنيد
Massachusetts General Hospital, Boston, Massachusetts, 02114, United States
Aleksandar Videnovic, MD, جهة اتصال, 671-724-3837, [email protected]
Aleksandar Videnovic, MD, المحقق الرئيسي
قيد التجنيد
Brigham and Womens Hospital, Boston, Massachusetts, 02115, United States
Daniel Gottlieb, MD, جهة اتصال
Daniel Gottlieb, MD, المحقق الرئيسي
Susan Redline, MD, محقق فرعي
قيد التجنيد
Boston Medical Center, Boston, Massachusetts, 02118, United States
Sanford Auerbach, MD, جهة اتصال
Sanford Auerbach, المحقق الرئيسي
Steven Lenio, محقق فرعي
قيد التجنيد
Beth Israel Deaconess Med. Ctr., Boston, Massachusetts, 02215, United States
Janet Mullington, MD, جهة اتصال
Janet Mullington, المحقق الرئيسي
Robert Thomas, محقق فرعي
قيد التجنيد
University of Massachusetts Memorial Medical Center, Worcester, Massachusetts, 01655, United States
Jennifer Wang, MD, جهة اتصال
Jennifer Wang, MD, المحقق الرئيسي
Evan Bradley, محقق فرعي
Mary Co, محقق فرعي
قيد التجنيد
New Jersey
Rutgers University - Robert Wood Johnson Medical School, New Brunswick, New Jersey, 08901, United States
Sabiha Hussain, MD, جهة اتصال
Sabiha Hussain, المحقق الرئيسي
Aesha Jobanputra, محقق فرعي
قيد التجنيد
New Mexico
University of New Mexico, Albuquerque, New Mexico, 87102, United States
Shanna Diaz, MD, جهة اتصال, 505-272-2515, [email protected]
Shanna Diaz, MD, المحقق الرئيسي
قيد التجنيد
New York
Icahn School of Medicine at Mount Sinai, New York, New York, 10029, United States
Vaishnavi Kundel, MD, جهة اتصال
Vaishnavi Kundel, MD, المحقق الرئيسي
Mira Tadros, محقق فرعي
قيد التجنيد
North Carolina
East Carolina University, Greenville, North Carolina, 27834, United States
Paul Bolin, MD, جهة اتصال
Paul Bolin, MD, المحقق الرئيسي
قيد التجنيد
Ohio
University of Cincinnati Medical Center, Cincinnati, Ohio, 45220, United States
Ann Romaker, MD, جهة اتصال
Ann Romaker, MD, المحقق الرئيسي
Rachel Foot, MD, محقق فرعي
قيد التجنيد
University Hospitals of Cleveland Medical Center, Cleveland, Ohio, 44106, United States
Kingman Strohl, MD, جهة اتصال
Kingman Strohl, MD, المحقق الرئيسي
Susheel Patil, محقق فرعي
قيد التجنيد
Oregon
Oregon Health and Science University, Portland, Oregon, 97239, United States
Hope Aluko, MD, جهة اتصال
Hope Aluko, المحقق الرئيسي
Akram Khan, محقق فرعي
Maureen Lyons, محقق فرعي
قيد التجنيد
Texas
Southwest Family Medicine Associates, Dallas, Texas, 75235, United States
Chrisette Sharma, MD, جهة اتصال, 469-893-1242, [email protected]
Chrisette Dharma, MD, المحقق الرئيسي
Angela Kemp, MD, محقق فرعي
Monica Ramirez, MD, محقق فرعي
قيد التجنيد
Houston Methodist Hospital, Houston, Texas, 77030, United States
Eleftherios Mylonakis, MD, جهة اتصال
Eleftherios Mylonakis, المحقق الرئيسي
Rodney Folz, محقق فرعي
Deepa Gotur, محقق فرعي
Faisal Zahiruddin, محقق فرعي
قيد التجنيد
University of Texas Health Science Center at Houston, Houston, Texas, 77030, United States
Reeba Matthew, MD, جهة اتصال
Reeba Matthew, MD, المحقق الرئيسي
Bela Patel, محقق فرعي
Ruckshanda Majid, محقق فرعي
قيد التجنيد
New Dawn Wellness and Medical Research Center, Houston, Texas, 77082, United States
Adanna Ukazu, MD, جهة اتصال
Adanna Ukazu, MD, المحقق الرئيسي
Kerollos Shaker, MD, محقق فرعي
Elaine Shehata, MD, محقق فرعي
قيد التجنيد
Virginia
University of Virginia Health System, Charlottesville, Virginia, 22908, United States
Alexandra Kadl, MD, جهة اتصال
Alexandra Kadl, MD, المحقق الرئيسي
Scott Schecter, MD, محقق فرعي
Jeffrey Sturek, MD.PhD, محقق فرعي
قيد التجنيد
Washington
Evergreen Hospital Medical Center, Kirkland, Washington, 98034, United States
Pinky Agarwal, MD, جهة اتصال
Pinky Agarwal, MD, المحقق الرئيسي
قيد التجنيد
West Virginia
University Physicians and Surgeons (DBA Marshall Health), Huntington, West Virginia, 25701, United States
Imran Khawaja, MD, جهة اتصال
Imran Khawaja, MD, المحقق الرئيسي
قيد التجنيد
West Virginia Clinical and Translational Science Institute, Morgantown, West Virginia, 26506, United States
Sunil Sharma, MD, جهة اتصال
Sunil Sharma, المحقق الرئيسي
Robert Stansbury, محقق فرعي
Edward Rojas, محقق فرعي
قيد التجنيد
Wisconsin
Medical College of Wisconsin, Milwaukee, Wisconsin, 53226, United States
Rose Franco, MD, جهة اتصال, 414-955-7040, [email protected]
Rose Franco, MD, المحقق الرئيسي
قيد التجنيد